partial least-squares discrimination analysis (pls-da) classification method Search Results


partial least squares-discriminant analysis (pls-da)  (RStudio)
90
RStudio partial least squares-discriminant analysis (pls-da)
Partial Least Squares Discriminant Analysis (Pls Da), supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/partial least squares-discriminant analysis (pls-da)/product/RStudio
Average 90 stars, based on 1 article reviews
partial least squares-discriminant analysis (pls-da) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
unscrambler x software  (CAMO Software)
90
CAMO Software unscrambler x software
Unscrambler X Software, supplied by CAMO Software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/unscrambler x software/product/CAMO Software
Average 90 stars, based on 1 article reviews
unscrambler x software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
metax software  (Metax GmbH)
90
Metax GmbH metax software
Metax Software, supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/metax software/product/Metax GmbH
Average 90 stars, based on 1 article reviews
metax software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
supervised partial least squares-discriminant analysis  (Metax GmbH)
90
Metax GmbH supervised partial least squares-discriminant analysis
Supervised Partial Least Squares Discriminant Analysis, supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/supervised partial least squares-discriminant analysis/product/Metax GmbH
Average 90 stars, based on 1 article reviews
supervised partial least squares-discriminant analysis - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
partial least squares discriminant analysis pls da models  (Umetrics)
86
Umetrics partial least squares discriminant analysis pls da models
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Partial Least Squares Discriminant Analysis Pls Da Models, supplied by Umetrics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/partial least squares discriminant analysis pls da models/product/Umetrics
Average 86 stars, based on 1 article reviews
partial least squares discriminant analysis pls da models - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
pls toolbox version 6.2.1  (Eigenvector Research Inc)
90
Eigenvector Research Inc pls toolbox version 6.2.1
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Pls Toolbox Version 6.2.1, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pls toolbox version 6.2.1/product/Eigenvector Research Inc
Average 90 stars, based on 1 article reviews
pls toolbox version 6.2.1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
partial least squares-discriminant analysis (pls-da)  (Addinsoft inc)
90
Addinsoft inc partial least squares-discriminant analysis (pls-da)
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Partial Least Squares Discriminant Analysis (Pls Da), supplied by Addinsoft inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/partial least squares-discriminant analysis (pls-da)/product/Addinsoft inc
Average 90 stars, based on 1 article reviews
partial least squares-discriminant analysis (pls-da) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
software version 2.0.0  (Metax GmbH)
90
Metax GmbH software version 2.0.0
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Software Version 2.0.0, supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/software version 2.0.0/product/Metax GmbH
Average 90 stars, based on 1 article reviews
software version 2.0.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
pls-da  (Metax GmbH)
90
Metax GmbH pls-da
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Pls Da, supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pls-da/product/Metax GmbH
Average 90 stars, based on 1 article reviews
pls-da - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
partial least-squares discrimination analysis (pls-da)  (Metax GmbH)
90
Metax GmbH partial least-squares discrimination analysis (pls-da)
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Partial Least Squares Discrimination Analysis (Pls Da), supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/partial least-squares discrimination analysis (pls-da)/product/Metax GmbH
Average 90 stars, based on 1 article reviews
partial least-squares discrimination analysis (pls-da) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
squares discriminant analysis pls da  (MathWorks Inc)
96
MathWorks Inc squares discriminant analysis pls da
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Squares Discriminant Analysis Pls Da, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/squares discriminant analysis pls da/product/MathWorks Inc
Average 96 stars, based on 1 article reviews
squares discriminant analysis pls da - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
partial-least squares discriminant analysis (pls-da)  (MedCalc Software Ltd)
90
MedCalc Software Ltd partial-least squares discriminant analysis (pls-da)
Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
Partial Least Squares Discriminant Analysis (Pls Da), supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/partial-least squares discriminant analysis (pls-da)/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
partial-least squares discriminant analysis (pls-da) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using partial least squares discriminant analysis (PLS-DA) shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease

Journal: Metabolomics

Article Title: NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures

doi: 10.1007/s11306-025-02363-8

Figure Lengend Snippet: Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using partial least squares discriminant analysis (PLS-DA) shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease

Article Snippet: Multivariate analysis (MVA) trough Principal component analysis (PCA) and partial-least-squares discriminant analysis (PLS-DA) models (SIMCA-P 11.5, Umetrics, Umeå, Sweden), were performed on full resolution 1 H NMR spectra, after unit variance (UV) scaling of the spectra.

Techniques: Metabolomic, Control

Supervised multivariate models and spectral features associated with mitochondrial disorders. I. Partial Least Squares Discriminant Analysis (PLS-DA) models were generated to compare patients with PMD to: A controls, B SMD, C . CKD stages 1–2, and D . CKD stages 3–5. The corresponding Q² values, indicate the predictive performance of each model. Clear discrimination was observed between PMD and controls (Q² = 0.53), and both CKD subgroups (Q² = 0.62 and 0.78). In contrast, the model comparing PMD to SMD showed lower predictive performance (Q² = 0.25), reflecting significant metabolic overlap. II. Corresponding loadings plot of model A, color-coded by variable importance in projection (VIP) scores for the first latent variable (LV1) highlighting spectral regions that contribute most to the separation between PMD and controls. (regions around 1.2–2.5 ppm and 3.0–4.5 ppm, consistent with metabolites involved in amino acid metabolism, organic acids, and energy-related pathways). Three-letter code used for amino acids. Abbreviations: 3-HBA: 3-hydroxybutyrate; 4-HPA: 4-hydroxyphenylacetate; N -PhAcGly: N -phenylacetylglycine. Ui: resonances at chemical shift i, which remain unassigned (or with tentative assignment)

Journal: Metabolomics

Article Title: NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures

doi: 10.1007/s11306-025-02363-8

Figure Lengend Snippet: Supervised multivariate models and spectral features associated with mitochondrial disorders. I. Partial Least Squares Discriminant Analysis (PLS-DA) models were generated to compare patients with PMD to: A controls, B SMD, C . CKD stages 1–2, and D . CKD stages 3–5. The corresponding Q² values, indicate the predictive performance of each model. Clear discrimination was observed between PMD and controls (Q² = 0.53), and both CKD subgroups (Q² = 0.62 and 0.78). In contrast, the model comparing PMD to SMD showed lower predictive performance (Q² = 0.25), reflecting significant metabolic overlap. II. Corresponding loadings plot of model A, color-coded by variable importance in projection (VIP) scores for the first latent variable (LV1) highlighting spectral regions that contribute most to the separation between PMD and controls. (regions around 1.2–2.5 ppm and 3.0–4.5 ppm, consistent with metabolites involved in amino acid metabolism, organic acids, and energy-related pathways). Three-letter code used for amino acids. Abbreviations: 3-HBA: 3-hydroxybutyrate; 4-HPA: 4-hydroxyphenylacetate; N -PhAcGly: N -phenylacetylglycine. Ui: resonances at chemical shift i, which remain unassigned (or with tentative assignment)

Article Snippet: Multivariate analysis (MVA) trough Principal component analysis (PCA) and partial-least-squares discriminant analysis (PLS-DA) models (SIMCA-P 11.5, Umetrics, Umeå, Sweden), were performed on full resolution 1 H NMR spectra, after unit variance (UV) scaling of the spectra.

Techniques: Generated